Lastly, the high expression of Fas ligand (FasL) on tumor ECs selectively eliminates effector CD8+ T cells instead of Tregs, which is attributed to the augmented level of cellular FLICE-inhibitory protein (c-FLIP) on Tregs (70). The gene discussed is CD8A; the disease is neoplasm.